Abstract
We conducted basic and clinical studies on the new oxacephem antibiotic 6315-S (flomoxef).
1) One gram or 2g of 6315-S were administered by i. v. drip infusion and concentrations in the uterus and accessory organs were measured. Tissue concentrations 1 hr after administration of 1g were: serum 8.3μg/ml, endometrium 4.0μg/g, myometrium 4.0μg/g, uterine cervix 4.0μg/g, ovary 6.0μg/g, and ovarian duct 3.4μg/g. Concentrations at 77±28.9 min. after administration of 2g were: serum 12.7±5.7μg/ml, endometrium 4.9±1.2μg/g myometrium 3.7±1.6μg/g, uterine cervix 4.0±1.0μg/g, ovary 6.7±2.7μg/g and ovarian duct 4.8±1.9μg/g. Tissue transfer of 6315-S therefore proved satisfactory.
2) 6315-S was administered to 11 patients with gynecological and obstetric infections by i. v. drip infusion at a dose of 1g, twice daily for 5-8 days. Diagnoses were pyometra in 3 patients, pelvic dead space inflammation in 3, pelvic peritonitis in 2, and vaginal cuff inflammation, vaginal abscess and puerperal fever in 1 patient each. Treatment was markedly effective in 1 patient, effective in 8 patients, and ineffective in 2, the efficacy rate being 81.8%.
No remarkable side effects were found. Regarding laboratory values, slight elevation of S-GOT and S-GPT was found in one case.
